LAG3 and neoplasm: Moreover, it was found that LAG‐3 was upregulated after anti‐PD‐L1 therapy resistance, thereby introducing a new way to monitor efficacy markers and immunotherapy resistance as well as overcome the challenges posed by tumor heterogeneity.